Comparative effects of SNX-7081 and SNX-2112 on cell cycle, apoptosis and Hsp90 client proteins in human cancer cells

Oncology Reports

Volumn 33, Issue 1, 2015, Pages 230-238

  Wang, Xiao ^a,b,c   Wang, Shaoxiang ^a,b,c   Liu, Yuting ^a   Huang, Dane ^d   Zheng, Kai ^a   Zhang, Yi ^a   Wang, Xiaoyan ^a   Liu, Qiuying ^a   Yang, Depo ^b   Wang, Yifei ^a  

^a JINAN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c Shenzhen University   (China)

^d Research Institute of Traditional Chinese Medicine   (China)

Author keywords

Apoptosis; Cell growth; Client proteins; Hsp90; SNX 2112; SNX 7081

Indexed keywords

HEAT SHOCK PROTEIN 90; INDOLE DERIVATIVE; PROTEIN INHIBITOR; SNX 2112; SNX 7081; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; FUSED HETEROCYCLIC RINGS; SNX-7081;

A375 CELL LINE; A549 CELL LINE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL LINE; CELL CYCLE; CELL GROWTH; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENCY; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HDF CELL LINE; HELA CELL LINE; HEP 2 CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IC50; K562 CELL LINE; L 02 CELL LINE; MCF 7 CELL LINE; MOLECULAR DOCKING; MRC5 CELL LINE; MTT ASSAY; PROTEIN BINDING; SW 620 CELL LINE; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SCREENING; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; BENZAMIDES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR DOCKING SIMULATION;

EID: 84916232566     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3552     Document Type: Article

References (38)

1. Taipale M, Jarosz DF and Lindquist S: HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11: 515-528, 2010.
2. Trepel J, Mollapour M, Giaccone G and Neckers L: Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537-549, 2010.
3. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
4. Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K and Giles FJ: Targeting HSP90 for cancer therapy. Br J Cancer 100: 1523-1529, 2009.
5. Banerji U, O'Donnell A, Scurr M, et al: Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23: 4152-4161, 2005.
6. Taldone T, Gozman A, Maharaj R and Chiosis G: Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 8: 370-374, 2008.
7. Goetz MP, Toft D, Reid J, et al: Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23: 1078-1087, 2005.
8. Chinn DC, Holland WS, Yoon JM, Zwerdling T and Mack PC: Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines. Pediatr Blood Cancer 58: 885-890, 2012.
9. Wang R, Shao F, Liu Z, et al: The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-kappaB and disruption of mitochondriadependent pathways. Chem Biol Interact 205: 1-10, 2013.
10. Wang SX, Ju HQ, Liu KS, et al: SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells. Biosci Biotechnol Biochem 75: 1540-1545, 2011.
11. Bachleitner-Hofmann T, Sun MY, Chen CT, et al: Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET inhibition. Clin Cancer Res 17: 122-133, 2011.
12. Liu KS, Liu H, Qi JH, et al: SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells. Cancer Lett 318: 180-188, 2012.
13. Crissman HA and Steinkamp JA: Rapid, simultaneous measurement of DNA, protein, and cell volume in single cells from large mammalian cell populations. J Cell Biol 59: 766-771, 1973.
14. Rajan A, Kelly RJ, Trepel JB, et al: A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 17: 6831-6839, 2011.
15. Huang KH, Veal JM, Fadden RP, et al: Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem 52: 4288-4305, 2009.
16. Best OG, Che Y, Singh N, Forsyth C, Christopherson RI and Mulligan SP: The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Leuk Lymphoma 53: 1367-1375, 2012.
17. Che Y, Best OG, Zhong L, et al: Hsp90 inhibitor SNX-7081 dysregulates proteins involved with DNA repair and replication and the cell cycle in human chronic lymphocytic leukemia (CLL) cells. J Proteome Res 12: 1710-1722, 2013.
18. Rice JW, Veal JM, Fadden RP, et al: Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum 58: 3765-3775, 2008.
19. Best OG, Singh N, Forsyth C and Mulligan SP: The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway. Br J Haematol 151: 185-188, 2010.
20. Barta TE, Veal JM, Rice JW, et al: Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90. Bioorg Med Chem Lett 18: 3517-3521, 2008.
21. Jin L, Xiao CL, Lu CH, et al: Transcriptomic and proteomic approach to studying SNX-2112-induced K562 cells apoptosis and anti-leukemia activity in K562-NOD/SCID mice. FEBS Lett 583: 1859-1866, 2009.
22. Lee YH, Lee NH, Bhattarai G, et al: PPARgamma inhibits inflammatory reaction in oxidative stress induced human diploid fibloblast. Cell Biochem Funct 28: 490-496, 2010.
23. Bettger WJ, Boyce ST, Walthall BJ and Ham RG: Rapid clonal growth and serial passage of human diploid fibroblasts in a lipidenriched synthetic medium supplemented with epidermal growth factor, insulin, and dexamethasone. Proc Natl Acad Sci USA 78: 5588-5592, 1981.
24. Huang D, Gu Q, Ge H, et al: On the value of homology models for virtual screening: discovering hCXCR3 antagonists by pharmacophore-based and structure-based approaches. J Chem Inf Model 52: 1356-1366, 2012.
25. Kawano T, Kobayakawa T, Fukuma Y, et al: A comprehensive study on the immunological reactivity of the Hsp90 molecular chaperone. J Biochem 136: 711-722, 2004.
26. Sreedhar AS, Kalmar E, Csermely P and Shen YF: Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 562: 11-15, 2004.
27. Hong DS, Banerji U, Tavana B, George GC, Aaron J and Kurzrock R: Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev 39: 375-387, 2013.
28. Marzec M, Eletto D and Argon Y: GRP94: an HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum. Biochim Biophys Acta 1823: 774-787, 2012.
29. Matassa DS, Amoroso MR, Maddalena F, Landriscina M and Esposito F: New insights into TRAP1 pathway. Am J Cancer Res 2: 235-248, 2012.
30. Kamal A, Thao L, Sensintaffar J, et al: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410, 2003.
31. Vilenchik M, Solit D, Basso A, et al: Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem Biol 11: 787-797, 2004.
32. Miyata Y: Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des 11: 1131-1138, 2005.
33. Harhaj EW and Sun SC: IKKgamma serves as a docking subunit of the IkappaB kinase (IKK) and mediates interaction of IKK with the human T-cell leukemia virus Tax protein. J Biol Chem 274: 22911-22914, 1999.
34. Mori N, Yamada Y, Ikeda S, et al: Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLVI-infected T-cell lines and primary adult T-cell leukemia cells. Blood 100: 1828-1834, 2002.
35. Zhou F, Zhang L, van Laar T, van Dam H and Ten Dijke P: GSK3β inactivation induces apoptosis of leukemia cells by repressing the function of c-Myb. Mol Biol Cell 22: 3533-3540, 2011.
36. Jin ZH, Kurosu T, Yamaguchi M, Arai A and Miura O: Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis. Oncogene 24: 1973-1981, 2005.
37. Jia XZ, Yang SY, Zhou J, et al: Inhibition of CHK1 kinase by Go6976 converts 8-chloro-adenosine-induced G2/M arrest into S arrest in human myelocytic leukemia K562 cells. Biochem Pharmacol 77: 770-780, 2009.
38. Davis JM, Navolanic PM, Weinstein-Oppenheimer CR, et al: Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res 9: 1161-1170, 2003.